866-997-4948(US-Canada Toll Free)

PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Cancer

No. of Pages : 160 Pages

PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

The PSA blood test and DREs are the most popular diagnostic tests for prostate cancer in Spain. PSA testing is also commonly used to monitor disease progression. Suspected disease is confirmed by TRUS-guided core needle biopsy, and metastases are identified using bone scans or CT scans (EAU, 2012). 

GlobalData’s primary research indicates that Spanish urologists and medical oncologists may slightly decrease their use of routine PSA screening to diagnose asymptomatic patients in response to the recent USPSTF recommendation against its use. As routine PSA screening is less frequently employed in Spain than in the US, and the USPSTF recommendation was not directed towards Spanish physicians, GlobalData believes that only a very small percentage of Spanish physicians will abide by this recommendation.

Scope
  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Spain from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Spain Prostate cancer market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Spain
  • Obtain sales forecast from 2012-2022 in Spain
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 15

4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 18
4.2.1 Conservative Management Strategies 22
4.2.2 Localized Treatments 23
4.2.3 Hormone Therapy 24
4.2.4 Drug Therapies 26
4.3 Spain 27
4.3.1 Diagnosis 27
4.3.2 Clinical Practice 27

5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles - Major Brands, Hormone Therapies 33
5.3.1 Zoladex (goserelin acetate) 33
5.3.2 Lupron Depot (leuprolide acetate) 36
5.3.3 Eligard (leuprolide acetate) 40
5.3.4 Trelstar (triptorelin acetate) 44
5.3.5 Firmagon (degarelix) 48
5.3.6 Casodex (bicalutamide) 51
5.4 Product Profiles - Major Brands, Chemotherapies 55
5.4.1 Taxotere (docetaxel) 55
5.4.2 Jevtana (cabazitaxel) 59
5.5 Product Profiles - Major Brands, Therapeutic Vaccines 63
5.5.1 Provenge (sipuleucil-T) 63
5.6 Product Profiles - Major Brands, Targeted Therapies 69
5.6.1 Zytiga (abiraterone acetate) 69
5.6.2 Xtandi (enzalutamide) 73
5.7 Product Profiles - Major Brands, Bone Therapies 77
5.7.1 Xgeva (denosumab) 77
5.7.2 Zometa (zoledronic acid) 80
5.8 Other Marketed Hormone and Drug Therapies 84

6 Opportunity and Unmet Need 85
6.1 Overview 85
6.2 Efficacy at Prolonging Overall Survival 86
6.3 Safety 86
6.4 Mitigation of Symptoms 87
6.5 Cost 87
6.6 Convenient Routes of Administration 87
6.7 Accurate Diagnostic Tests and Surveillance Tools 88
6.8 Unmet Needs Gap Analysis 88
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 90

7 Pipeline Assessment 91
7.1 Overview 91
7.2 Promising Drugs in Clinical Development 92
7.2.1 Cabozantinib 94
7.2.2 Custirsen Sodium 98
7.2.3 Sprycel (dasatinib) 103
7.2.4 Yervoy (ipilimumab) 108
7.2.5 Orteronel 113
7.2.6 Alpharadin (radium-223 chloride) 117
7.2.7 Tasquinimod 123
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 127

8 Market Outlook 131
8.1 Spain 131
8.1.1 Forecast 131
8.1.2 Key Events 134
8.1.3 Drivers and Barriers 134

9 Appendix 136
9.1 Bibliography 136
9.2 Abbreviations 139
9.3 Methodology 142
9.4 Forecasting Methodology 142
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 142
9.4.2 Percent Drug-treated Patients 143
9.4.3 Percent Hormone Therapy-Treated Patients 143
9.4.4 Drugs Included in Each Therapeutic Class 143
9.4.5 Launch, Patent and Market Exclusivity Expiry Dates 144
9.4.6 General Pricing Assumptions 145
9.4.7 Individual Drug Assumptions 147
9.4.8 Generic Erosion 156
9.4.9 Pricing of Pipeline Agents 156
9.5 Physicians and Specialists Included in This Study 158
9.6 Survey of Prescribing Physicians 158
9.7 About the Authors 159
9.7.1 Authors 159
9.7.2 Global Head of Healthcare 160
9.8 About GlobalData 161
9.9 Contact Us 161
9.10 Disclaimer 161

List of Table


Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 20
Table 5: Leading Treatments for Prostate Cancer, 2012 31
Table 6: Product Profile - Zoladex 33
Table 7: Zoladex SWOT Analysis, 2012 35
Table 8: Product Profile - Lupron Depot 36
Table 9: Lupron Depot SWOT Analysis, 2012 38
Table 10: Product Profile - Eligard 40
Table 11: Eligard SWOT Analysis, 2012 42
Table 12: Product Profile - Trelstar 44
Table 13: Trelstar SWOT Analysis, 2012 46
Table 14: Product Profile - Firmagon 47
Table 15: Firmagon SWOT Analysis, 2012 49
Table 16: Product Profile - Casodex 51
Table 17: Casodex SWOT Analysis, 2012 53
Table 18: Product Profile - Taxotere 55
Table 19: Taxotere SWOT Analysis, 2012 57
Table 20: Product Profile - Jevtana 59
Table 21: Jevtana SWOT Analysis, 2012 61
Table 22: Product Profile - Provenge 62
Table 23: Provenge SWOT Analysis, 2012 67
Table 24: Product Profile - Zytiga 69
Table 25: Zytiga SWOT Analysis, 2012 71
Table 26: Product Profile - Xtandi 73
Table 27: Xtandi SWOT Analysis, 2012 75
Table 28: Product Profile - Xgeva 77
Table 29: Xgeva SWOT Analysis, 2012 79
Table 30: Product Profile - Zometa 80
Table 31: Zometa SWOT Analysis, 2012 82
Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 83
Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 84
Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment 85
Table 35: Clinical Unmet Needs - Gap Analysis, 2012 88
Table 36: Prostate Cancer - Phase III Pipeline, 2012 91
Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 91
Table 38: Product Profile - Cabozantinib 93
Table 39: Cabozantinib SWOT Analysis, 2012 97
Table 40: Product Profile - Custirsen Sodium 98
Table 41: Custirsen Sodium SWOT Analysis, 2012 102
Table 42: Product Profile - Sprycel 103
Table 43: Sprycel SWOT Analysis, 2012 106
Table 44: Product Profile - Yervoy 107
Table 45: Yervoy SWOT Analysis, 2012 111
Table 46: Product Profile - Orteronel 112
Table 47: Orteronel SWOT Analysis, 2012 116
Table 48: Product Profile - Alpharadin (radium-223 chloride) 117
Table 49: Alpharadin SWOT Analysis, 2012 121
Table 50: Product Profile - Tasquinimod 122
Table 51: Tasquinimod SWOT Analysis, 2012 125
Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 126
Table 53: ProstVac SWOT Analysis, 2012 129
Table 54: Sales Forecasts ($m) for Prostate Cancer in Spain, 2012-2022 131
Table 55: Key Events Impacting Sales for Prostate Cancer in Spain, 2012-2022 133
Table 56: Prostate Cancer Market in Spain - Drivers and Barriers, 2012 133
Table 57: Key Launch Dates 143
Table 58: Key Patent Expiries and Market Exclusivity Expiries 144
Table 59: Physicians Surveyed, By Country 157

List of Chart


Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 19
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 92
Figure 3: Sales for Prostate Cancer in Spain by Drug Class, 2012-2022 132

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *